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ABSTRACT
The pharmacokinetics of penicillin G and ampicillin are reviewed as they pertain to their potential
use in in vitro therapy. (C) 1996 Wiley-Liss, Inc.
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he molecular structure of the penicillins con-
sists of a thiazolidine ring connected to a
[3-1actam ring attached to a side chain. The side
chain determines many of the pharmacologic char-
acteristics of a given penicillin. The presence of an
amino group on the benzyl side chain distinguishes
ampicillin from benzylpenicillin (penicillin G),
which is one example ofthe many chemical variants
of penicillin resulting from alterations of this side
chain attached to the basic 6 amino-penicillinoic
acid molecule.
Recently, the issue of the relative superiority
of penicillin G vs. ampicillin for in utero therapy
has been raised. Amstey and Gibbs wrote an edi-
torial opinion stating that the "favorable pharmaco-
kinetics of penicillin G and its narrower and
specific spectrum make this a better choice for
group B streptococcal (GBS) prophylaxis than
ampicillin This editorial opinion has stimu-
lated a growing ambiguity about the peripartal use
ofampicillin. The purpose of this review is to exam-
ine the key points of these contentions and, in so
doing, clarify the issue of ampicillin vs. penicillin
G for in utero therapy and GBS prophylaxis.
LITERATURE REVIEW
A review of the literature on penicillin G and ampi-
cillin reveals a dearth of pharmacokinetic data on
penicillin G in pregnant subjects and extensive data
on ampicillin in such patients.
2-9 A partial explana-
tion emanates from the fact that penicillin G was
widely used prior to the evolution of pharmacoki-
netics into a distinct discipline. When ampicillin
was introduced in the early 1960s, pharmacokinetics
was the "new kid on the block," thus having the
benefit of investigation through these newly
evolved scientific methods. Being the focus of at-
tention in the literature, ampicillin came to be con-
sidered the [3-1actam of choice and the utilization
of penicillin G gradually faded.
THEORETICAL FACTORS GOVERNING
TRANSPORT OF ANTIBIOTICS ACROSS
THE PLACENTAL BARRIER
Anatomically, the placenta is composed of ectoder-
mal cells, a basement membrane, mesodermally de-
rived tissue, another basement membrane, and fetal
endothelial cells. The only other embryologic
structure in the human body derived from ectoderm
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and mesoderm as opposed to mesoderm and endo-
derm is the choroid plexus. Not surprisingly, the
antibiotic transports across these 2 membranes
strongly parallel each other. The factors governing
antibiotic transport across the placental are 1) mo-
lecular size, 2) degree of protein binding, 3) degree
of ionization, and 4) lipid solubility.
Molecular Size
The comparability of the size of penicillin G and
ampicillin is such that this factor per se is not a
significant determinant for differential transport of
these 2 antibiotics.
Degree of Protein Binding
Penicillin G is moderately bound to albumin in the
sera of normal and pregnant subjects (65% bound
compared with ampicillin’s 20%). 3,5,7 To be pharma-
cologically active, an antibiotic must exist in its
unbound state. The amount of antibiotic available
for transport in a given time is a direct function of
the concentration of free drug. Once the antibiotic
is removed by transport, the equilibrium between
bound and unbound drug is reestablished. The free
drug entering the fetal vascular compartment and
amniotic fluid is once again subjected to similar
protein binding interactions which reduce the
amount of antibiotic available for biologic activity.
One of the keys to effective in utero therapy con-
cerns how much pharmacologically active antibiotic
appropriate to the bacteria in question can be deliv-
ered in a relatively limited time.
Degree of Ionization
Both penicillin G (pKa 2.8 for its free carboxylic-
acid group) and ampicillin (pKa 2.5 for its free
carboxylic-acid group and pKa 7.2 for its free
amino group) are highly ionized (>99.9%) under
physiologic conditions.1 Thus, this factor has little
impact on defining the relative rate of placental
transfer.
Lipid Solubility
Both penicillin and ampicillin antibiotics exhibit
only moderate lipophilicity. The oil/water partition
coefficients (Ko/w) are 0.55 and 0.16 for penicillin G
and ampicillin, respectively (isobutanol vs.
pH 7.4 aqueous buffer).
1 However, in general, a
difference of a factor of 3-4 in Ko/w will have only
moderate effects on drug permeability. Fundamen-
tally, these characteristics simply slow the rate of
placental transfer but do not prevent such transfer.
COMPARATIVE PHARMACOKINETICS OF
AMPICILLIN AND PENICILLIN G IN
PREGNANCY
Intravenous Administration
A review of the literature failed to identify any
comparative pharmacokinetic studies of ampicillin
and penicillin G in pregnant subjects receiving both
drugs intravenously. Hence, direct intraindividual
comparison of parameters such as volume of distri-
bution, clearance, and half-life has not been made.
Indeed, a recent review of this topic suggested that
much of our knowledge of penicillin G pharmacoki-
netics in pregnancy is based on a number of very
early and semiquantitative reports,
Intramuscular Administration
In what is perhaps the most comprehensive compar-
ative study of these 2 drugs, identical intramuscular
doses were given at various times during pregnancy
with maternal, fetal, and amniotic-fluid sampling.
Ampicillin appears to yield consistently higher (ap-
proximately 50%) maternal and fetal serum concen-
trations than penicillin G. However, its level in
amniotic fluid is substantially lower than that of
penicillin G during the first 2 h following adminis-
tration. After 3 h, superior and ultimately therapeu-
tic concentrations of ampicillin appear in the amni-
otic fluid.
Ampicillin Pharmacokinetics
In contrast to penicillin G, the pharmacokinetics of
ampicillin have been studied thoroughly, z’8’9 It has
been established that pregnantwomen exhibit renal
clearances and total body clearances that are about
50% greater than those under control conditions.
These control studies were performed 3-12 months
after delivery when normal menstruation had re-
sumed and breast-feeding had ceased. The oral bio-
availability was very similar during pregnancy and
3-12 months postpartum (approximately 50%), and
the recovery of the drug in the urine was essentially
unaffected by pregnancy. 6’7 Furthermore, studies of
the reproducibility of ampicillin levels following
repeated administration of the drug to the same
subject have demonstrated the dose proportionality
of the area under the plasma-concentration time
curve. Studies of the serum concentration in the
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mother following the administration ofthe drug into
the amniotic fluid have been performed.
Finally, MacAulay et al. studied the transfer-
ence of ampicillin within the maternal serum, fetal
serum, and amniotic-fluid compartments. A transfer
occurs from mother to fetus within minutes, but
the antibiotic concentrations in the amniotic fluid
are minimal for 60 min and potentially therapeutic
levels for susceptible bacteria are not achieved until
90 min has elapsed. Therefore, the amniotic fluid
appears to become a depository for the ampicillin.
gence of a resistant subpopulation of a previously
susceptible strain which then becomes the domi-
nant population. A prime example of this phenome-
non was the abuse of kanamycin during the 1970s
in newborn intensive care units (NICUs) which
resulted in K. pneumoniae isolates that were resistant
to virtually all the aminoglycosides available at that
time. Another prime example of induced resistance
is the change in the avidity of binding of penicillin
to the penicillin-binding proteins of selected strains
of Streptococcus pneumoniae.
USE OF PENICILLIN G VS. AMPICILLIN FOR
GBS PROPHYLAXIS
Spectrum of Susceptibility
Once pharmacologically significant levels ofan anti-
biotic are attained in the fetal compartment, the key
question governing the biologic effectiveness is the
spectrum of susceptibility of the organism involved.
Both penicillin G and ampicillin share a common
spectrum of activity against gram-positive bacteria.
However, minor differences exist. For example, the
minimum inhibitor concentrations (MIC) for ampi-
cillin are lower for enterococci and Listeria monocyto-
logenes, whereas penicillin G is more effective than
ampicillin for hemolytic streptococci. This superior
MIC for the [3-hemolytic streptococci does not nec-
essarily translate into biologic significance.The clear
difference between penicillinG and ampicillin is the
latter’s extended spectrum for gram-negative bacte-
ria, specifically Escherichia coli, Proteus mirabilis, Sal-
monella species, and Haemophilus influenzae.
The concept of ampicillin’s selecting for resis-
tance emanates from a case series published by
McDuffie et al. lz These authors reported 4 cases of
Enterobacteriaceae chorioamnionitis in gravidas who
had received ampicillin prophylaxis for premature
rupture of the fetal membranes and GBS carriage.
Three of the isolates were E. coli. The fourth case
was due to Klebsiella pneumoniae. Two of the resul-
tant neonates died with fulminant perinatal septice-
mia. The rationale for publication of their manu-
script was the contention that these isolates were
examples of "adverse perinatal outcomes due to
selection or overgrowth of resistant organisms re-
sulting from the use of ampicillin."
Induced Resistance
Prolonged use (especially associated with subopti-
mal dosing) of an antibiotic can select for the emer-
Intrinsic Resistance
If an antibiotic is used against a bacterium whose
spectrum of susceptibility is not encompassed by
that drug, one cannot anticipate having a true bio-
logic effect. Approximately 35-40% of all current
E. coli isolates are resistant to ampicillin. This resis-
tance is mediated primarily by the presence of sig-
nificant quantities of [3-1actamases within the peri-
plasmic space. More than 95% of all K. pneumoniae
isolates are similarly inherently resistant to ampicil-
lin. When isolated instances of disease due to En-
terobacteriaceae occur in the face of ampicillin ther-
apy, the probability is that the same pattern of
disease would have been observed had ampicillin
not been given. Unless one is dealing with a phe-
nomenon such as anaerobic progression or the use
of antibiotics which has an impact on 30S or 50S
ribosomes, ineffective antibiotics will not alter the
progress of monoetiologic disease.
Drug chemoprophylaxis with ampicillin alters
the incidence of disease by diminishing the denom-
inator, thus magnifying the impact of the numera-
tor. As a consequence, perception of the relative
importance of an isolate is changed. McDuffie et
al. lz could not adequately approximate the number
of cases of perinatal septicemia adequately treated
with ampicillin. Therefore, no rigorous risk/benefit
analysis can be performed.
CONCLUSIONS
Because of the limited comparative data available
for penicillin G, it is overly assertive to contend
that the pharmacokinetic advantages of penicillin
G in pregnancy warrant its selection over ampicillin.
Similary, the data regarding the spectrum of suscep-
tibility clearly show that ampicillin is the more ver-
satile antibiotic, while the available data on the
selection of resistant stains are best regarded as
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tentative such that validation through prospective
study is required. Thus, it appears that ampicillin
is superior to penicillin G in the clinical settings of
in utero therapy.
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